AngioDynamics Inc is primarily active in the medical device industry.

The main competitors of AngioDynamics Inc in the market include Medtronic Inc, Boston Scientific Corporation, and Johnson & Johnson.

AngioDynamics Inc. is a leading medical technology company specializing in the development and manufacture of innovative medical devices used in minimally invasive procedures. The company was founded in 1988 and is headquartered in Latham, New York. AngioDynamics Inc. has a rich history of delivering cutting-edge solutions in areas such as vascular access, peripheral vascular disease, and oncology. With a commitment to improving patient outcomes, AngioDynamics Inc. has established itself as a trusted provider of advanced medical devices to healthcare professionals worldwide. The company's dedication to research, development, and clinical collaboration ensures continued success in the field of minimally invasive interventions.

AngioDynamics Inc has achieved several significant milestones throughout its existence. One notable accomplishment includes the development and commercialization of innovative medical devices for the treatment of peripheral vascular disease and cancer. The company has also expanded its global presence by successfully introducing its products in various international markets. Furthermore, AngioDynamics Inc has received numerous accolades and recognition for its breakthrough technologies, including the FDA approval of its groundbreaking radiofrequency ablation system. With a steadfast commitment to improving patient outcomes, AngioDynamics Inc continues to make strides in the field of medical technology and remains at the forefront of innovation.

AngioDynamics Inc is primarily present in the United States.

AngioDynamics Inc represents values of innovation, patient focus, and commitment to improving medical treatments. The company's corporate philosophy revolves around developing and delivering breakthrough medical technologies that enhance patient care and improve the quality of life. AngioDynamics is dedicated to providing innovative solutions for minimally invasive, image-guided medical procedures, with a focus on delivering superior outcomes for patients. With a strong emphasis on research and development, AngioDynamics continuously strives to advance medical technologies, ensuring patient safety, and revolutionizing the field of medical interventions.

Analysts currently set an average price target of 19,72 USD for the AngioDynamics stock (median: 18,36 USD), implying +25,2 % versus the latest price. The consensus is based on 10 analyst ratings.

AngioDynamics Analytikerens Kursmål 2026

10 analysts currently rate the AngioDynamics stock: 9 recommend buying, 1 holding and 0 selling.

AngioDynamics Analytikerens Kursmål 2026

Converted at the current exchange rate, the AngioDynamics share trades at 13,65 EUR (15,75 USD).

The AngioDynamics share (ANGO) is listed on 2 stock exchanges, including: NASDAQ (ANGO), Frankfurt (UG2.F).

AngioDynamics Inc. is a leading company in the field of minimally invasive medicine and offers innovative medical technology solutions for vascular diseases, cancer treatment, and interventional radiology. The company operates globally and distributes its products in over 90 countries. The company operates in three main business areas: Vascular Access, Peripheral Vascular, and Oncology. The Vascular Access area includes products such as port systems, catheters, and accessories used to create long-term vascular access for patients requiring repeated blood draws or infusions. The Peripheral Vascular area includes products such as atherectomy systems, thrombectomy systems, and stent systems used for the treatment of peripheral vascular diseases such as atherosclerosis and thrombosis. Oncology offers a wide range of products and systems for cancer treatment, including catheters and port systems. Another important area of AngioDynamics is interventional radiology. The company offers innovative instruments and systems for the diagnosis and treatment of diseases such as liver tumors and prostate enlargement. Products in this area include microwave-assisted tumor ablation systems, needles, catheters, and accessories. AngioDynamics is also a key player in the field of medical imaging. The company provides systems for navigation and visualization of catheters and instruments used in minimally invasive procedures. These products enable physicians to perform precise and safe procedures and offer patients faster recovery. The business model of AngioDynamics is based on the development and marketing of innovative medical solutions that improve the treatment of vascular diseases, cancer, and other diseases. The company invests in research and development to develop new products and technologies that meet the needs of physicians and patients. Additionally, the company collaborates closely with hospitals and medical facilities to ensure rapid adoption and dissemination of its products. AngioDynamics has a strong and diverse product line that enables the company to serve various markets and customers. The company offers high-quality products and solutions that are valued in medical practice worldwide. With its leadership role in research and development of minimally invasive medicine, AngioDynamics is well positioned to continue growing and maintaining its position as a leading company in the industry. Overall, AngioDynamics' business model is focused on providing innovative medical products and solutions that improve the treatment of vascular diseases, cancer, and other diseases. The company operates in multiple business areas and has a strong presence in the global market. With its extensive product line, leadership role in research and development, and close collaboration with hospitals and medical facilities, AngioDynamics is well positioned to maintain its leading role in the industry in the future.

-omsætningen for AngioDynamics er 320,17 Mio. USD. Dette tal er baseret på aktuelle finansielle data og afspejler virksomhedens forretningsydeevne.

-overskuddet for AngioDynamics er -36,74 Mio. USD. Nettooverskuddet afspejler virksomhedens rentabilitet efter fradrag af alle udgifter.

Pris-til-indtjening-forholdet (P/E) for AngioDynamics er i øjeblikket -17,80. P/E-forholdet sammenligner den nuværende aktiekurs med indtjeningen pr. aktie og hjælper investorer med at vurdere værdiansættelsen af AngioDynamics-aktien.

Pris-til-salgs-forholdet (P/S) for AngioDynamics er i øjeblikket 2,04. P/S-forholdet sammenligner markedskapitalisering med årlig omsætning og fungerer som en værdiansættelsesmetrik for AngioDynamics-aktien.

AlleAktien-kvalitetsscore for AngioDynamics er 2/10.

ISIN for AngioDynamics er US03475V1017. ISIN (International Securities Identification Number) er en globalt unik identifikator for værdipapirer.

WKN for AngioDynamics er A0B9A5. WKN (Wertpapierkennnummer) er et seks-cifret tysk identifikationsnummer for værdipapirer.

Tickeren for AngioDynamics er ANGO. Tickersymbolet bruges til at handle AngioDynamics-aktier på børsen.

AngioDynamics har udbetalt dividende hvert år i de seneste 0 år.

AngioDynamics er klassificeret i sektoren 'Sundhed'.

Dividenderne fra AngioDynamics udloddes i USD.